News
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...
The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above. Moderna expects to have the vaccine available for the 2025-2026 ...
Previously, Jivi was approved in September 2018 for adults and adolescents aged 12 years and older with this hemophilia subtype. 2 According to data collected from federally funded hemophilia ...
May 18 (UPI) --The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.The agency approved the vaccine only for people 65 and older ...
WASHINGTON (AP) — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional ...
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they ...
Gilead Sciences, Inc.GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV.. The regulatory body approved lenacapavir, under the ...
Washington — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions.. Novavax makes the nation’s only traditional ...
The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...
The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit future shots to older Americans and people at higher risk of serious ...
Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should be targeted by updated versions of the vaccines.
FDA’s additional request for placebo-controlled trials in people ages 50 to 64 is based on inconsistent lower age limits in other countries’ COVID-19 booster recommendations, Prasad said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results